AI Article Synopsis
- * After screening potential compounds, one showed strong Atg4B inhibitory effects, effectively blocking autophagy triggered by anti-castration-resistant prostate cancer (CRPC) drugs and increasing cancer cell apoptosis.
- * By optimizing the structure of this compound, we created a new drug that effectively inhibits Atg4B while minimizing its impact on phospholipase A, suggesting its use as an additional therapy alongside anti-CRPC treatments.
Article Abstract
Autophagy inhibition is an attractive target for cancer therapy. In this study, we discovered inhibitors of Atg4B essential for autophagosome formation and evaluated their potential as therapeutics for prostate cancer. Seventeen compounds were identified as candidates after screening and a thermal shift assay. Among them, compound showed the most potent Atg4B inhibitory activity, inhibited autophagy induced by anti-castration-resistant prostate cancer (CRPC) drugs, and significantly enhanced apoptosis. Although has been known as a phospholipase A (PLA) inhibitor, other PLA inhibitors had no effect on Atg4B and autophagy. We then performed structural optimization based on molecular modeling and succeeded in developing (by shortening the alkyl chain of ), which was a potent competitive inhibitor for Atg4B ( = 3.1 μM) with declining PLA inhibitory potency. Compound enhanced the anticancer activity of anti-CRPC drugs autophagy inhibition. These findings suggest that can be used as an adjuvant drug for therapy with anti-CRPC drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.1c02113 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reply to: Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.
J Clin Oncol
January 2025
Fred Saad, MD, University of Montreal, Montreal, QC, Canada; Egils Vjaters, MD, P. Stradinš Clinical University Hospital, Riga, Latvia; Isabella Testa, MD, Bayer S.p.A, Milan, Italy; and Kunhi Parambath Haresh, MD, All India Institute of Medical Sciences, New Delhi, India.
Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.
J Clin Oncol
January 2025
Abhenil Mittal, MD, DM, MBBS and Geordie Linford, MD, MSc, BSc, Department of Oncology, Northeast Cancer Center, Health Sciences North, Sudbury, ON, Canada, Division of Clinical Sciences, Northern Ontario School of Medicine, ON, Canada; and Bishal Gyawali, MD, PhD, FASCO, Department of Oncology, Queen's University, Kingston, ON, Canada, Department of Public Health Sciences, Queen's University, Kingston, ON, Canada, Division of Cancer Care and Epidemiology, Queen's University, Kingston, ON, Canada.
Kidney and gallbladder stones and the risk of prostate cancer: Results from the EPICAP study.
PLoS One
January 2025
UVSQ, Inserm, Gustave Roussy, CESP, Université Paris-Saclay, Villejuif, France.
Background: Prostate cancer remains the most frequent cancer among men, representing a significant health burden. Despite its high morbidity and mortality rates, the etiology of prostate cancer remains relatively unknown, with only non-modifiable established risk factors. Chronic inflammation has emerged as a potential factor in prostate carcinogenesis.
View Article and Find Full Text PDFSynthesis, Preclinical Evaluation, and First-in-Human Assessment of ICG-PSMA-D5: A PSMA-Targeted Probe for Fluorescence-Guided Surgery of Prostate Cancer.
J Med Chem
January 2025
Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
Precise surgical resection of prostate cancer (PCa) is a significant clinical challenge due to the impact of positive surgical margins on postoperative outcomes. Fluorescence-guided surgery (FGS) enables real-time tumor visualization using fluorescent probes. In this study, we synthesized and evaluated an indocyanine green (ICG)-based PSMA-targeted near-infrared probe, , for intraoperative imaging of PCa lesions.
View Article and Find Full Text PDFAdvancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.
J Zhejiang Univ Sci B
January 2025
Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!